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Previewsthan 600 cases. There, it mostly serves as
a nucleating environment to fold distant
intramolecular structural elements and
form a hydrophobic core crucial for the
global fold (Figure 2D). Thus, in the C-
pole, the pathogen elegantly mimicked
a native recognition element (the tandem
PxxP repeats), empowered it with disor-
der, and optimized it further by emulating
an additional recognition assembling ele-
ment employed in the core of a globular
protein fold. The work by Aitio et al.
(2012) is significant, because it highlights
how a pathogen protein can exhibit its
prowess in manipulating its host through
mastering disorder and fine tuning of
stereoelectronics. Further approaches to
decode the structural mechanism that
multiple EspFU 47-residue repeats func-
tion in a synergistic and concerted way
will be required to shed light on the arrayof tools that pathogens elegantly exploit
to manipulate their host.REFERENCES
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In this issue of Structure, de Leon-Boenig and colleagues bring to light several key characteristics of NF-kB
inducing kinase (NIK), which is at the center of many pathological disorders, using an impressive body of
structural and functional studies. Structures of NIK described here provide deep insights into themechanism
of NIK activity regulation and may facilitate the design of new generation inhibitors for therapeutic use.Transcription factor NF-kB is activated by
the members of tumor necrosis factor
receptor (TNFR) and Toll-like receptor
through two major signal transduction
pathways: canonical and alternative. The
central regulatory component of the
alternative pathway is NIK, also known
as MAP3K14. Although initially identified
as a potent inducer of the canonical
pathway, NIK was subsequently shown
to function in the canonical pathway only
in a receptor-specific manner. The sig-
nificance of NIK became apparent after
the discovery of the defect in p100
processing in alymphoplasia mice where
NIK is constitutively active due to a muta-
tion (Razani et al., 2011). In the alternative
NF-kB activation pathway, a subset ofTNFR upon ligand binding activates
NIK, which cooperates with IKK1 to
induce the processing of the precursor
protein p100 into NF-kB subunit p52.
Although details still need to be worked
out, the NIK activation process is distinct
from other known kinases. In the resting
cell, NIK is continuously degraded by the
actions of E3 ligases and proteasome
(Figure 1). Mutations in these negative
regulators of NIK as well as in NIK itself
that lead to NIK accumulation have
emerged as one of the major causes of
NF-kB deregulation in many cancers of
hematologic origin (Staudt, 2010). Thus,
NIK represents a promising therapeutic
target for the treatment of autoimmune
disorders and cancers. In this issue ofStructure, de Leon-Boenig et al. (2012)
report X-ray structures of the catalytic
kinase domains of both human and
mouse NIK, where they show that the
kinase domain maintains an active con-
formation. Similar work by Liu et al.
(2012) confirms the finding. As discussed
below, these structures are significant
for two reasons: (1) they propose a new
mode of kinase activity regulation, and
(2) the NIK structural models can be
used to develop new inhibitors.
Toappreciate thesignificanceofhowthe
structures explain a new mode of kinase
activity regulation, it is essential to know
the general structural features of protein
kinase that distinguish between active
and inactive states. Whereas the inactive2012 Elsevier Ltd All rights reserved 1615
Figure 1. Activation of Alternative NF-kBSignaling Pathway through
NIK Stabilization
Under normal conditions, the E3 ligase complex (TRAF2:TRAF3:cIAP1:cIAP2)
directs NIK for ubiquitination and proteasomal degradation by binding to the
N-terminal domain of NIK (yellow), which results in the cellular NIK concen-
tration below the threshold required for function. Upon stimulation, the
TRAF2:TRAF3 complex is recruited to the receptor. Newly synthesized
NIK accumulates and activates IKK1, which triggers the p100 processing.
No phosphorylation is needed for NIK activation. The active conformation of
NIK kinase domain (blue) is stabilized by segments (red and green) flanking
the kinase domain. The salt bridge (black dot) between Lys429h and
Glu440h (blue and red zigzag) signify the active state of NIK. The C-terminal
domain (magenta) of NIK is thought to bind IKK1.
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Previewsform of a kinase can adopt
many conformations, only
one conformationof theactive
site dictates its activity.
Structures of NIK reveal that,
like all protein kinases, the
NIK kinase domain is com-
prised of two lobes: a small
N-terminal lobe and a large
C-terminal helical lobe. The
b sheet between b6 and b9
uses three hydrogen bonds,
and the hydrophobic spines
connecting the two lobes
are intact. The DFG motif is
in the ‘‘in’’ conformation, and
the catalytically important
salt bridge is formed between
two invariant residues,
Lys429h (superscript ‘‘h’’
denotes human sequence)
and Glu440h. All of these
structural features are consis-
tent with the active conforma-tion of a protein kinase (Nolen et al.,
2004). In most cases, to achieve the active
conformation, at least one residue in the
activation loop is required to be phosphor-
ylated. In the case of NIK, it is generally
accepted in the field that Thr559h in the
activation loop is that residue which
undergoes phosphorylation during NIK
activation (Lin et al., 1998). Structures of
NIK reported by two different groups,
some of which have been determined at
very high resolution, show no evidence of
phosphorylation at this position. Exhaus-
tive analysis by mass spectrometry also
could not identify any p-Thr at position
559h. As a final confirmation, de Leon-
Boenig et al. (2012) show that mutation
of Thr559h to Ala or Asp exhibits similar
activity. These structures also provide
compelling reasoning as to why this
residue should not be phosphorylated.
Thr559h makes direct hydrogen bonding
contactwith the catalytic aspartate residue
located within the catalytic loop. A phos-
phate group would make an incompatible
electrostatic environment resulting in a
significant change of the active site. These
observations suggest NIK activation is
through other mechanisms rather than
phosphorylation in the activation loop.
This is not unexpected, sinceNIKwasclas-
sified as a non-RD kinase where no
conserved Arg preceding the catalytic
aspartate needs to be neutralized by
a phosphate linked to an activation loop1616 Structure 20, October 10, 2012 ª2012 Eresidue. Then how does NIK maintain its
active conformation? It is possible that
the nonkinase extensions at the N- and C
termini might be responsible for holding
the kinase in the catalytically active state
allosterically. The N-terminal segment
prior to the canonical kinase domain folds
into a helix-strand-helix motif, packing
against the b sheet and the ac helix in the
small lobe. This structural arrangement is
reminiscent of Aurora kinases bound to
their allosteric activators INCENP and
TPX (Sessa et al., 2005). The C-terminal
extension of NIK also makes extensive
contacts with the large lobe at the bottom
of the kinase. Although it needs experi-
mental proof, allosteric regulation of NIK
catalytic activity byboth flanking segments
that negate the requirement for additional
modifications has not been observed
before.
The E3 ligase regulatory complex,
TRAF2:TRAF3:cIAP1:cIAP2, interacts with
the N-terminal domain (residues 1–325)
of NIK (Figure 1). The most fascinat-
ing feature of the NIK activity regu-
lation through the alternative NF-kB sig-
naling pathway is its dissociation from
the negative E3 ligase regulatory complex
induced by the ligand binding to the
receptor. Once these regulators are
captured by the receptors, new NIKmole-
cules become instantly ready to act on its
substrates, IKK1 and p100, without
requiring further action in trans for its cata-lsevier Ltd All rights reservedlytic activity (Figure 1). Thus,
one signal, rather thanmultiple
signals, is sufficient for NIK
activation. Mutation of any of
the negative regulators result-
ing in NIK stabilization can
transmit the downstream
signal unperturbed, causing
uncontrolled growth. Large
scale sequencing efforts in
cancer patients have re-
vealed that in many cancers
of hematologic origin, such as
multiple myeloma, diffuse
large B cell lymphomas, and
mucosal associated lymphoid
tissue (MALT) lymphomas,
components of the alternative
NF-kB signaling pathway
are mutated (Staudt, 2010).
The current reports explain
oncogenic transformation in
MALT lymphomas. In these
lymphomas, the API2-MALTfusion oncoprotein cleaves NIK at residue
Arg325, releasing active NIK from nega-
tive regulation (Rosebeck et al., 2011). As
revealed by these structures, the central
domain of NIK (residues 327h to 673h)
contains all necessary information to
maintain the catalytic activity of NIK.
The article by de Leon-Boenig et al.
(2012) also describes how NIK interacts
with three tight binding small molecule
inhibitors: two (aminothiazolyl)phenol
containing compounds and one alkynylin-
doline compound. These compounds
bind primarily to the nucleotide binding
near the gate keeper residue at the hinge
region, with some variations in binding
near the glycine rich loop that communi-
cates with the large lobe. One significant
outcome of this research is that a conser-
vative species-specific variation (Valm to
Leuh) at the hinge region shows selectivity
in inhibitor binding. Therefore, caution
must be taken to extrapolate information
from mouse to human. In general, struc-
tural analysis of several free and inhib-
itor-bound structures of human and
mouse NIK provide a wealth of informa-
tion to design new inhibitors for thera-
peutic purposes. Finally, one must appre-
ciate the vast body of experiments
presented, which includes the generation
of over one hundred constructs and mu-
tants, their expression and purification
from baculovirus infected cells and deter-
mination of over ten structures.
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In this issue of Structure, Shumilin and colleagues show the power of metabolite screening bymeans of X-ray
crystallography to link an orphan protein domain with an orphan biochemical function. This result paves the
way for large-scale functional annotation and sets new objectives for structural genomics.Whole-genome sequences constitute a
major breakthrough toward the complete
and fine description of most organisms.
Functional annotation of genes and the
function of proteins they encode was ex-
pected to be efficiently guided by genome
comparison and systematic scrutiny by
identifying sequence similarities, gene
neighbors (using the Rosetta stone ap-
proach), and similar strategies developed
over the last decade. Sequence com-
parisons have led to the classification of
protein sequences into families, such as
in the Pfam database (Punta et al.,
2012). It highlighted the existence of
thousands of domains of unknown func-
tion (DUFs; Bateman et al., 2010). In
parallel, structural genomics initiatives
focused on creating a library of all existing
protein folds. Indeed, protein structures
can help to reveal remote similarities and
accordingly extend the repertoire of anno-
tated genes. However, progress toward
achieving this goal has been slow, and
roughly two thousand of the newly solved
structures have no known function.At the same time, traditional biochem-
ical characterization has been partially
neglected over the last two decades,
and we witnessed a shift in education
and research trends toward the more
attractive genetic, cellular and large-scale
omics approaches. In this context, the
recent disclosure of the rising knowl-
edge gap between biochemical function
and sequence information can be seen
as a therapeutic shock (Lespinet and
Labedan, 2005). Limitations appear at
both ends of the annotation problem: not
only many genes are still awaiting func-
tional annotation, but a vast repertoire of
biochemical functions have yet to be
linked to a known gene. About a third
of known enzymatic activities (EC
numbers; http://www.chem.qmul.ac.uk/
iubmb/enzyme/) defined by the Nomen-
clature Committee of the International
Union of Biochemistry and Molecular
Biology are not associated with any
macromolecule in major public data-
bases. The estimated 1,525 orphan activ-
ities (EC numbers without associatedsequences) are found in all classes
of enzymes and in all kingdoms of life
(Chen and Vitkup, 2007). Quite surpris-
ingly, some of these unannotated genes
or orphan activities are found conserved
across thousands of living organisms.
In this issue of Structure, Shumilin et al.
(2012) selected three proteins whose
crystal structures were solved by a struc-
tural genomics consortium but whose
function remained to be characterized.
They cleverly chose a set of proteins that
well illustrated the current challenge for
function annotation. Two proteins, YxkO
from Bacillus subtilis and AI-BP from
mouse, each harbor a DUF (named ac-
cording to their Pfam codes: PF01256
and Yjef_N, respectively). Both protein
families contain thousands of members in
a wide range of organisms (from bacteria,
archea to eukaryotes, including human).
Sequence similarities connected YxkO to
the ATP-dependent ribokinase-like super-
family. This was confirmed by the X-ray
structure of the apo-enzyme, but the
nature of the second substrate remained2012 Elsevier Ltd All rights reserved 1617
